tiprankstipranks
The Fly

Monopar Therapeutics initiated with an Overweight at Piper Sandler

Monopar Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Monopar Therapeutics (MNPR) with an Overweight rating and $72 price target The firm thinks Monopar’s two distinct therapeutic pursuits represent value potential far exceeding the company’s current market cap. While these two programs – radiotherapeutics utilizing a unique new oncology target and a small molecule copper mobilizer with “impressive” proof of concept data in Wilson disease – “are quite disparate,” they collectively represent meaningful upside to current levels, the analyst tells investors in a research note.

Discover the Best Stocks and Maximize Your Portfolio:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1